Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: Results from a randomized, double-blind, placebo-controlled trial

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorTONIOLO, Ricardo Alexandre
dc.contributor.authorFERNANDES, Francy de Brito Ferreira
dc.contributor.authorSILVA, Michelle
dc.contributor.authorDIAS, Rodrigo da Silva
dc.contributor.authorLAFER, Beny
dc.date.accessioned2017-12-12T13:19:39Z
dc.date.available2017-12-12T13:19:39Z
dc.date.issued2017
dc.description.abstractBackground: Depressive episodes and cognitive impairment are major causes of morbidity and dysfunction in individuals suffering from bipolar disorder (BD). Novel treatment approaches that target clinical and cognitive aspects of bipolar depression are needed, and research on pathophysiology suggests that mitochondrial modulators such as the nutraceutical creatine monohydrate might have a therapeutic role for this condition. Methods: Eighteen (N=18) patients with bipolar depression according to DSM-IV criteria who were enrollled in a 6-week, randomized, double-blind, placebo-controlled trial of creatine monohydrate 6 g daily as adjunctive therapy were submitted to neuropsychological assessments (Wisconsin Card Sorting Test, Digit Span subtest of the Wechsler Adult Intelligence Scale-Third Edition, Stroop Color-Word Test, Rey-Osterrieth complex figure test, FAS Verbal Fluency Test) at baseline and week 6. Results: There was a statistically significant difference between the treatment groups of the change on the total scores after 6 weeks in the verbal fluency test, with improvement in the group receiving adjunctive treatment with creatine. We did not find significant differences between the groups of the changes on other neuropsychological tests. Limitations: Small sample and lack of a control group of healthy subjects. Conclusions: Our trial, which was the first to investigate the cognitive effects of creatine monohydrate on bipolar depression, indicates that supplementation with this nutraceutical for 6 weeks is associated with improvement in verbal fluency tests in patients with this condition.
dc.description.indexMEDLINE
dc.description.sponsorshipNARSAD Independent Investigator Award from the Brain & Behavior Research Foundation [20202]
dc.description.sponsorshipBrazilian Federal research grants
dc.description.sponsorshipCNPq
dc.description.sponsorshipCAPES
dc.identifier.citationJOURNAL OF AFFECTIVE DISORDERS, v.224, Special Issue, p.69-75, 2017
dc.identifier.doi10.1016/j.jad.2016.11.029
dc.identifier.eissn1573-2517
dc.identifier.issn0165-0327
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/24342
dc.language.isoeng
dc.publisherELSEVIER SCIENCE BV
dc.relation.ispartofJournal of Affective Disorders
dc.rightsrestrictedAccess
dc.rights.holderCopyright ELSEVIER SCIENCE BV
dc.subjectBipolar disorder
dc.subjectDepression
dc.subjectCognition
dc.subjectAdjunctive therapy
dc.subjectCreatine monohydrate
dc.subjectRandomized controlled trial
dc.subject.othermagnetic-resonance-spectroscopy
dc.subject.otherhuman brain
dc.subject.other1st-degree relatives
dc.subject.otheroral supplementation
dc.subject.othersymptomatic status
dc.subject.othereuthymic patients
dc.subject.otheryoung-adults
dc.subject.otherdisorder
dc.subject.othermetaanalysis
dc.subject.otherperformance
dc.subject.wosClinical Neurology
dc.subject.wosPsychiatry
dc.titleCognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: Results from a randomized, double-blind, placebo-controlled trial
dc.typearticle
dc.type.categoryreview
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus18
hcfmusp.contributor.author-fmusphcRICARDO ALEXANDRE TONIOLO
hcfmusp.contributor.author-fmusphcFRANCY DE BRITO FERREIRA
hcfmusp.contributor.author-fmusphcMICHELLE DA SILVA
hcfmusp.contributor.author-fmusphcRODRIGO DA SILVA DIAS
hcfmusp.contributor.author-fmusphcBENY LAFER
hcfmusp.description.beginpage69
hcfmusp.description.endpage75
hcfmusp.description.issueSpecial Issue
hcfmusp.description.volume224
hcfmusp.origemWOS
hcfmusp.origem.pubmed27890303
hcfmusp.origem.scopus2-s2.0-85007135374
hcfmusp.origem.wosWOS:000413368300010
hcfmusp.publisher.cityAMSTERDAM
hcfmusp.publisher.countryNETHERLANDS
hcfmusp.relation.referenceArts B, 2008, PSYCHOL MED, V38, P771, DOI 10.1017/S0033291707001675
hcfmusp.relation.referenceAstin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
hcfmusp.relation.referenceBalanza-Martinez V, 2010, EUR J PHARMACOL, V626, P87, DOI 10.1016/j.ejphar.2009.10.018
hcfmusp.relation.referenceBauer IE, 2015, J PSYCHIATR RES, V62, P115, DOI 10.1016/j.jpsychires.2015.01.008
hcfmusp.relation.referenceBauer M, 2015, INT J BIPOLAR DISORD, V3, DOI 10.1186/s40345-015-0029-x
hcfmusp.relation.referenceBearden CE, 2001, BIPOLAR DISORD, V3, P106, DOI 10.1034/j.1399-5618.2001.030302.x
hcfmusp.relation.referenceBenkert O, 1997, J NERV MENT DIS, V185, P151, DOI 10.1097/00005053-199703000-00004
hcfmusp.relation.referenceBerk M, 2011, NEUROSCI BIOBEHAV R, V35, P804, DOI 10.1016/j.neubiorev.2010.10.001
hcfmusp.relation.referenceBora E, 2009, J AFFECT DISORDERS, V113, P1, DOI 10.1016/j.jad.2008.06.009
hcfmusp.relation.referenceClay HB, 2011, INT J DEV NEUROSCI, V29, P311, DOI 10.1016/j.ijdevneu.2010.08.007
hcfmusp.relation.referencede Almeida KM, 2012, CNS NEUROSCI THER, V18, P160, DOI 10.1111/j.1755-5949.2011.00240.x
hcfmusp.relation.referenceDechent P, 1999, AM J PHYSIOL-REG I, V277, pR698
hcfmusp.relation.referenceDepp CA, 2016, PSYCHIAT CLIN N AM, V39, P95, DOI 10.1016/j.psc.2015.09.004
hcfmusp.relation.referenceDepp CA, 2012, BIPOLAR DISORD, V14, P217, DOI 10.1111/j.1399-5618.2012.01011.x
hcfmusp.relation.referenceDepp CA, 2012, J AFFECT DISORDERS, V136, P812, DOI 10.1016/j.jad.2011.09.035
hcfmusp.relation.referenceFirst M, 1996, STRUCTURED CLIN INTE
hcfmusp.relation.referenceGoodwin GM, 2008, EUR NEUROPSYCHOPHARM, V18, P787, DOI 10.1016/j.euroneuro.2008.07.005
hcfmusp.relation.referenceGuy W., ECDEU ASSESSMENT MAN
hcfmusp.relation.referenceHAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278
hcfmusp.relation.referenceHammett ST, 2010, NEUROSCI LETT, V479, P201, DOI 10.1016/j.neulet.2010.05.054
hcfmusp.relation.referenceHeaton R., 1981, WISCONSIN CARD SORTI
hcfmusp.relation.referenceHu XP, 2012, NEUROIMAGE, V62, P1103, DOI 10.1016/j.neuroimage.2012.03.005
hcfmusp.relation.referenceJager R, 2011, AMINO ACIDS, V40, P1369, DOI 10.1007/s00726-011-0874-6
hcfmusp.relation.referenceJudd LL, 2003, INT J NEUROPSYCHOPH, V6, P127, DOI 10.1017/S1461145703003341
hcfmusp.relation.referenceJudd LL, 2002, ARCH GEN PSYCHIAT, V59, P530, DOI 10.1001/archpsyc.59.6.530
hcfmusp.relation.referenceKalra EK, 2003, AAPS PHARMSCI, V5
hcfmusp.relation.referenceKato T, 1996, J NEUROPSYCH CLIN N, V8, P417
hcfmusp.relation.referenceKay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937
hcfmusp.relation.referenceKe Y, 2000, PSYCHIAT RES-NEUROIM, V100, P169, DOI 10.1016/S0925-4927(00)00075-5
hcfmusp.relation.referenceKemp DE, 2014, J AFFECT DISORDERS, V169, pS34, DOI 10.1016/S0165-0327(14)70007-2
hcfmusp.relation.referenceKemp DE, 2010, BIPOLAR DISORD, V12, P404, DOI 10.1111/j.1399-5618.2010.00823.x
hcfmusp.relation.referenceKurtz MM, 2009, NEUROPSYCHOLOGY, V23, P551, DOI 10.1037/a0016277
hcfmusp.relation.referenceLing J, 2009, BEHAV PHARMACOL, V20, P673, DOI 10.1097/FBP.0b013e3283323c2a
hcfmusp.relation.referenceLyoo IK, 2003, PSYCHIAT RES-NEUROIM, V123, P87, DOI 10.1016/S0925-4927(03)00046-5
hcfmusp.relation.referenceLyoo IK, 2012, AM J PSYCHIAT, V169, P937, DOI 10.1176/appi.ajp.2012.12010009
hcfmusp.relation.referenceMcMorris T, 2006, PSYCHOPHARMACOLOGY, V185, P93, DOI 10.1007/s00213-005-0269-z
hcfmusp.relation.referenceMONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382
hcfmusp.relation.referenceNierenberg AA, 2013, AUST NZ J PSYCHIAT, V47, P26, DOI 10.1177/0004867412449303
hcfmusp.relation.referenceNortje G, 2013, J AFFECT DISORDERS, V150, P192, DOI 10.1016/j.jad.2013.05.034
hcfmusp.relation.referenceOhtsuki S, 2002, J CEREBR BLOOD F MET, V22, P1327, DOI 10.1097/01.WCB.0000033966.83623.7D
hcfmusp.relation.referencePost RM, 2010, J CLIN PSYCHIAT, V71, P1176, DOI 10.4088/JCP.08m04811yel
hcfmusp.relation.referenceQuraishi S, 2002, J AFFECT DISORDERS, V72, P209, DOI 10.1016/S0165-0327(02)00091-5
hcfmusp.relation.referenceRae C, 2003, DEV NEUROSCI-BASEL, V25, P324, DOI 10.1159/000073509
hcfmusp.relation.referenceRae C, 2003, P ROY SOC B-BIOL SCI, V270, P2147, DOI 10.1098/rspb.2003.2492
hcfmusp.relation.referenceRae CD, 2015, NEUROCHEM INT, V89, P249, DOI 10.1016/j.neuint.2015.08.010
hcfmusp.relation.referenceRakofsky JJ, 2011, CNS SPECTRUMS, V16, P11, DOI 10.1017/S1092852912000119
hcfmusp.relation.referenceRango M, 1997, MAGNET RESON MED, V38, P878, DOI 10.1002/mrm.1910380605
hcfmusp.relation.referenceRawson ES, 2008, PHYSIOL BEHAV, V95, P130, DOI 10.1016/j.physbeh.2008.05.009
hcfmusp.relation.referenceRey A, 1999, REVISAO TECNICA TRAD
hcfmusp.relation.referenceRobinson LJ, 2006, J AFFECT DISORDERS, V93, P105, DOI 10.1016/j.jad.2006.02.016
hcfmusp.relation.referenceAlves CRR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076301
hcfmusp.relation.referenceRosa Adriane R, 2007, Clin Pract Epidemiol Ment Health, V3, P5, DOI 10.1186/1745-0179-3-5
hcfmusp.relation.referenceSAPPEYMARINIER D, 1992, J CEREBR BLOOD F MET, V12, P584
hcfmusp.relation.referenceSarris J, 2016, AM J PSYCHIAT, V173, P575, DOI 10.1176/appi.ajp.2016.15091228
hcfmusp.relation.referenceSarris J, 2015, WORLD PSYCHIATRY, V14, P370, DOI 10.1002/wps.20223
hcfmusp.relation.referenceSarris J, 2011, BIPOLAR DISORD, V13, P454, DOI 10.1111/j.1399-5618.2011.00945.x
hcfmusp.relation.referenceSchlattner U, 2006, BBA-MOL BASIS DIS, V1762, P164, DOI 10.1016/j.bbadis.2005.09.004
hcfmusp.relation.referenceSerretti A, 2013, J PSYCHOPHARMACOL, V27, P616, DOI 10.1177/0269881113485143
hcfmusp.relation.referenceSILVER IA, 1994, J NEUROSCI, V14, P5068
hcfmusp.relation.referenceSpreen O, 1998, COMPENDIUM NEUROPSYC, P213
hcfmusp.relation.referenceSylvia LG, 2011, J PSYCHIATR PRACT, V17, P224, DOI 10.1097/01.pra.0000398419.82362.32
hcfmusp.relation.referenceTorres IJ, 2007, ACTA PSYCHIAT SCAND, V116, P17, DOI 10.1111/j.1600-0447.2007.01055.x
hcfmusp.relation.referenceTurner CE, 2015, J NEUROSCI, V35, P1773, DOI 10.1523/JNEUROSCI.3113-14.2015
hcfmusp.relation.referenceWALLIMANN T, 1992, BIOCHEM J, V281, P21
hcfmusp.relation.referenceWatanabe A, 2002, NEUROSCI RES, V42, P279, DOI 10.1016/S0168-0102(02)00007-X
hcfmusp.relation.referenceWechsler D, 2011, TEX WASI 2 WECHSLER
hcfmusp.relation.referenceWechsler D, 1997, WAIS 3 ADM SCOR MAN
hcfmusp.relation.referenceWyss M, 2000, PHYSIOL REV, V80, P1107
hcfmusp.relation.referenceYOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429
hcfmusp.relation.referenceZahodne LB, 2014, J AM GERIATR SOC, V62, P130, DOI 10.1111/jgs.12600
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication3906b773-ecb4-4d21-9ae9-c3eff3886c6d
relation.isAuthorOfPublicationfc11bc70-f740-4f59-864b-2babc29d30d5
relation.isAuthorOfPublicationf1f4521c-d352-4b1f-ad19-6f8c4df42fe7
relation.isAuthorOfPublicationb37c7931-c261-4259-8959-eab55718fdd2
relation.isAuthorOfPublication717693ba-66ff-4dac-9ac5-86d07eafb715
relation.isAuthorOfPublication.latestForDiscovery3906b773-ecb4-4d21-9ae9-c3eff3886c6d
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_TONIOLO_Cognitive_effects_of_creatine_monohydrate_adjunctive_therapy_in_2017.PDF
Tamanho:
253.38 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion(English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21